High Risk WHO Grade II Glioma Clinical Trial
Official title:
A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas
Verified date | February 2020 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot study of a vaccination regime that is designed to efficiently induce anti-tumor T-cell responses in patients with WHO grade II glioma. The proposed regime with BTIC Lysate in combination with imiquimod, an FDA-approved immune response modifier will induce potent anti-glioma immune response with minimal or no toxicity.
Status | Completed |
Enrollment | 19 |
Est. completion date | November 8, 2018 |
Est. primary completion date | November 8, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Cohort 1 and 2: Age =18 year old with histologically diagnosed World Health Organization (WHO) grade II astrocytoma or oligoastrocytoma with "high-risk" factors - defined as: - age = 40 with any extent resection; - age 18-39 with incomplete resection (post-op MRI showing >1cm residual disease, based on the maximum dimension of residual T2 or fluid-attenuated inversion-recovery [FLAIR] abnormality from the edge of the surgical cavity either laterally, anteroposteriorly, or superoinferiorly) or - age 18-39 with neurosurgeon-defined gross total resection (GTR) but the tumor size is = 4 cm (the maximum preoperative tumor diameter, based on the axial and/or coronal T2 or FLAIR MR images) Cohort 3: Age =18 year old with histologically diagnosed WHO grade II glioma with recurrence - Karnofsky performance status = 60% - Clinically stable and off corticosteroids for at least 4 weeks prior to study enrollment - Adequate organ function within 14 days of study registration including: - Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) =1.0 x 109/L, platelets =100 x 109/L; hemoglobin = 8 g/dL - Hepatic: - Total bilirubin = 1.5 x upper limit of normal (ULN) for age and SGPT (ALT) = 2.5 x upper limit of normal (ULN) for age - Renal: Normal serum creatinine or creatinine clearance =60 ml/min/1.73 m2 Exclusion Criteria: - History of immune system abnormalities such as hyperimmunity (e.g., autoimmune diseases) that required systemic immunosuppression therapy and hypoimmunity (e.g., myelodysplastic disorders, marrow failures, AIDS, ongoing pregnancy, transplant immunosuppression) - Any isolated laboratory abnormality suggestive of a serious autoimmune disease (e.g. hypothyroidism) - Any conditions that could potentially alter immune function (AIDS, multiple sclerosis, diabetes, renal failure) - Receiving ongoing treatment with immunosuppressive drugs, excluding those patients requiring dexamethasone for treatment of tumor-related edema - Currently receiving any investigational agents or registration on another therapy based trial - Pregnant or lactating |
Country | Name | City | State |
---|---|---|---|
United States | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Frank Lieberman | University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity (DLT) | The incidence and severity of adverse events associated with the vaccine regime will be assessed according to NCI's Common Terminology Criteria for Adverse Events V 4.0 (CTCAE), as follows: . Grade 3-5 vaccine related allergic reaction . Grade 3-5 organ toxicity (cardiac, dermatologic (excluding localized skin reaction), gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic) not pre-existing or due to the underlying malignancy and occurring within 28 days of vaccination and of any length in duration . Grade 2 -5 autoimmune reactions (such as hypothyroidism) |
Two Years | |
Primary | Induction of BTIC Lysate-specific T-cell response | We will determine the response rate and magnitude of immune response in post-vaccine peripheral blood mononuclear cells (PBMC) against the BTIC Lysate in response to this form of vaccine, using IFN-enzyme-linked immuno-spot (ELISPOT) assays. | Two Years |